Unity Biotechnology Inc (NAS:UBX)
$ 0.999 -0.036 (-3.48%) Market Cap: 16.83 Mil Enterprise Value: 9.10 Mil PE Ratio: 0 PB Ratio: 1.19 GF Score: 32/100

UNITY Biotechnology Inc To Discuss Phase 2 ENVISION Program Update Call Transcript

Mar 27, 2023 / 12:00PM GMT
Release Date Price: $1.95 (-53.01%)
Operator

Good morning and welcome to the UNITY Biotechnology conference call and webcast. (Operator Instructions) As a reminder, this call is being recorded and a replay will be made available on the UNITY website following the conclusion of the event.

I'd now like to turn the call over to Lynne Sullivan, Chief Financial Officer of UNITY Biotechnology. Please go ahead, Lynn.

Lynne Sullivan
Unity Biotechnology, Inc. - CFO, Head of Corporate Development

Thanks, Tara. Good morning, and thank you for joining UNITY Biotechnology's conference call to review the 24-week data from Part A of the Phase 2 ENVISION study of UBX1325 in patients with wet AMD.

With me on today's call is Anirvan Ghosh, the CEO of UNITY Biotechnology; Jamie Dananberg, our Chief Medical Officer; myself, Lynne Sullivan, the Chief Financial Officer; and we are fortunate to have Dr. Arshad Khanani, Managing Partner and Director of Clinical Research at Sierra Eye Associates, joining us for today's webcast.

Before turning the call over to Anirvan, I'd like to remind you that

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot